Home
This site is intended for healthcare professionals

Precision Decisions in Metastatic Prostate Cancer: Module 3 Treating Managing toxicity and sustaining treatment

Share

Description

This program is supported by an independent education grant from Pfizer. This education program is only available to healthcare professionals in the USA.

Credits: AMA PRA Category 1 Credits™ (0.25.00 hours)

Type of activity: Enduring material (On-demand)

Launch date: September 16th 2026

Expiration date: December 31st 2027

Estimated time to complete this activity: 15 minutes

Prefer to read instead? Read our Key Clinical Summary here.

This is Module 3 of a three-part on-demand series: Module 1 and Module 2.

Activity Description

Join expert Dr. Shawn Dason, MD, for a practical, case-based exploration of how to proactively manage toxicities and sustain therapy in patients receiving PARP inhibitor combination regimens for metastatic prostate cancer. This session examines regimen-specific adverse event profiles—including severe anemia, neutropenia, and fatigue—and offers actionable strategies for dose modifications, complete blood count (CBC) monitoring, and managing drug-drug interactions. Through real-world clinical vignettes, participants will explore how to coordinate multidisciplinary care handovers across medical oncology, urology, pharmacy, and nursing to optimize adherence and maintain treatment continuity.

Session Highlights

  • Apply evidence-based algorithms to manage hematologic toxicities, such as PARP inhibitor-induced anemia, using structured hold, transfusion, and dose-reduction protocols to sustain treatment.
  • Implement regimen-specific CBC monitoring schedules and proactively evaluate treatable underlying causes of fatigue and cytopenias.
  • Navigate critical administration requirements, drug-drug interactions, and medication adherence strategies, leveraging pharmacy collaboration to prevent therapeutic failure.
  • Strengthen multidisciplinary care coordination and care-handover pathways across oncology, urology, pharmacy, and nursing teams to minimize care gaps during treatment.

Who Should Participate?

This program is designed for healthcare professionals directly involved in the diagnosis, targeted treatment, and longitudinal management of patients with metastatic prostate cancer (mPC), who seek to implement guideline-concordant genomic testing and multidisciplinary care into routine clinical practice.

  • Oncology and Urology Practitioners (Academic and Community)
  • Oncology Nurses
  • Nurse Practitioners
  • Physician Assistants
  • Pharmacists
  • Genetic Counselors
  • Other Healthcare Professionals involved in the care and treatment of patients with mPC

Faculty

Dr Shawn Dason

Dr Shawn Dason is an Associate Professor of Urology and urologic oncologist at The Ohio State University, specializing in the surgical management of genitourinary cancers, including prostate cancer. His clinical expertise includes robotic and minimally invasive approaches to prostate cancer, with a focus on delivering individualized treatment tailored to each patient’s goals and needs. Dr Dason takes a multidisciplinary approach to care, working closely with colleagues across specialties to optimize outcomes. His research focuses on advancing innovative approaches to urologic cancer treatment and improving patient care.

Continuing Education Information

Commercial support: This activity received monetary support through an independent education grant from Pfizer.

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Disclosures

Dr Shawn Dason has no financial relationships within the past 24 months with any ineligible companies. Dr Dason does not intend to discuss non-FDA uses of drug products and/or devices only in relation to products for which he has no financial relationships.

These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education.

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible companies. All relevant financial relationships for anyone associated with the content of this activity were mitigated prior to the release of this program.

Activity Accreditation for Health Professions

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

  • When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
  • Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.

Participation Costs

There is no cost to participate in this program.

This continuing education activity is active starting September 16th 2026, and will expire on December 31st 2027..

Estimated time to complete this activity: 15 minutes.

Learning objectives

By the end of this education. HCPs will be able to:

Implement standardized, guideline-concordant HRR biomarker testing workflows in patients with mPC:

  • Identify patients eligible for germline and somatic HRR testing, including non-BRCA mutations.
  • Determine appropriate timing and testing modality within the clinical pathway.
  • Interpret test results to inform eligibility for targeted therapies within real-world workflows.

Apply emerging clinical evidence on PARPi-based therapies to guide treatment selection and sequencing in mPC:

  • Interpret clinical data on efficacy, safety, and biological rationale for PARPi-based combination strategies.
  • Select appropriate patients for PARPi combination strategies across mCSPC and mCRPC.
  • Determine optimal sequencing of therapies based on disease stage, biomarkers, and patient factors.

Manage treatment-related toxicities and coordinate multidisciplinary care for patients receiving PARPi-based therapies:

  • Identify and mitigate common hematologic and gastrointestinal adverse events (AEs) associated with PARPi combination therapies.
  • Apply dose modification and supportive care strategies to maintain treatment continuity in practice.
  • Coordinate multidisciplinary input to optimize safety, adherence, and patient outcomes.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

Hi, my name is Sean Dayson, and I'm a urologic oncologist at the Ohio State University Cancer Center in Columbus, Ohio. Before I begin, here are my disclosures. Uh, I don't have any disclosures. So, uh, really excited to talk to you a little bit about this topic today. So the topic is going to be managing toxicity and sustaining treatment. Here, learning objective 3 is to manage treatment-related toxicity, coordinating with the multidisciplinary team, and maintain the patient on effective therapy. In PARP inhibitor trials, 14% of patients, roughly 1 in 7, discontinued treatment because of an adverse event, and approximately 27% required a dose reduction. So that means more than 25% of patients require a dose modification and 1 in 7 discontinue therapy altogether. Uh, these discontinuations represent a patient who lost access to a potentially beneficial therapy, and most toxicity is manageable when it's anticipated and addressed early. The organizing principle here is to anticipate, monitor, and modify treatment rather than abandon it. So just to start out this discussion, um, we're gonna poll you and. Ask, how confident are you in managing grade 3 anemia in a patient on a PARP inhibitor plus ARPI combination? You can select whether you're not at all confident, slightly confident, moderately confident, or very confident, and hopefully these answers will improve after this discussion. To start in with our case vignette. This case involves a 74-year-old man with metastatic castration resistant prostate cancer and a BRCA2 alteration. This patient population is most likely to derive a benefit from a PARP inhibitor. He is being treated with a PARP inhibitor plus hormonal therapy combination and an ARPI with a favorable PSA response. At three months into treatment, he reports fatigue that limits his daily activity without bleeding or other overt symptoms. Serial hemoglobin values show a progressive decline 13.2 g at a baseline, 10.4 g at month two, and 7.6 g at month three. Three questions frame the remainder of this discussion. Whether to hold, reduce, transfuse, or continue therapy, what should be worked at first and which additional team members should be involved with his care, this case is revisited later in the module. So the first principle of monitoring is that it's not uniform across agents. It's a regimen specific and defined in the US prescribing information for each drug, and the label for each specific agent should be followed. Akiga, the combination of nerapirib and abiraterone, specifies an intensive early monitoring schedule. A complete blood count weekly for the first month, every 2 weeks through months 2 and 3, and monthly thereafter for the remainder of the first year. This contrasts with olaporib or Linparsa, which requires a baseline count followed by monthly monitoring, and talazoperib calzenna, which also specifies monthly monitoring. The more intensive early monitoring for Akiga reflects the timing of toxicity onset. Intelapro 3, anemia of any grade occurred in 71% of patients, fatigue in 28%, and neutropenia in 27%. Hematologic toxicity with these combinations is common rather than exceptional, which is why monitoring is front loaded to permit early intervention. The monitoring schedule should be matched to specific label rather than applying a single generic monthly interval to all patients. Anemia is the most common hematologic toxicity of PARP inhibitor therapy. Anemia in monotherapy studies was the leading contributor to the 27% rate of dose reduction and 14% rate of discontinuation attributable to grade 3 to 4 toxicity. The underlying mechanism is that PARP inhibitors trap the PARP enzyme on DNA within red cell precursors in the bone marrow. This is an on-target class effect rather than an allergic or idiosyncratic reaction, and it's characteristically front loaded. Onset typically occurs within the 1st 2 to 3 months of treatment, followed by a plateau. This time course is consistent with the hemoglobin nadir observed at month 3 in the case under discussion. Thrombocytopenia is a further hematologic toxicity of note and more prominent with nerapirib. Fatigue and GI symptoms are also observed. Anemia, however, is the predominant toxicity of this class. When the hemoglobin declines, the first step before any dose modification is to investigate treatable causes iron deficiency, B12, folate deficiency, thyroid dysfunction, bleeding. I would emphasize that the consensus panel rated this initial workup as the single highest priority step ahead of transfusion or dose modification. The drug should not be presumed responsible by default, since this patient could be equally well iron deficient or have an occult gastrointestinal bleed. Specifically, in the prostate cancer population, recurrent hematuria could also be a certain cause. Management then follows a grid defined by the hemoglobin band and by whether the patient is stable or symptomatic. Stability is defined as a hemoglobin decline of less than 2 g from the patient's own baseline. A decline exceeding 2 g or the presence of symptoms defines instability. In the mild band, 8 to 10 g, a stable patient requires no change in therapy. In the moderate band, 7 to 8 g, a stable patient should have therapy held and restarted at a reduced dose. A symptomatic patient in the same band should be transfused, held. And restart it at a reduced dose. Below 7 g, transfusion is indicated regardless of symptoms. One further point of emphasis, the specific agent judged responsible should be held rather than the entire combination by default. When the components are administered as separate agents, it's often possible to hold the PARP inhibitor while continuing the hormonal agent. To continue on to some of the other side effects, fatigue, nausea, thrombocytopenia, and neutropenia are common. While anemia receives particular attention, each of these remaining toxicities has its own management approach. For fatigue, non-pharmacologic measures are the first line, with pharmacologic interventions reserved for fatigue severe enough to limit self-care. For nausea and vomiting, ondansetron is the first line antiemetic. 6 or more vomiting episodes in 24 hours despite treatment is a reasonable threshold to consider discontinuation. For thrombocytopenia, therapy should be held when the platelet count falls below 75,000 and permanent discontinuation should be considered below 25,000. For neutropenia, an absolute neutrophil count between 500 and 1000 is the threshold for holding therapy, and a count at or below 500 warrants holding therapy with a subsequent dose reduction. The governing principle throughout is to hold the suspected agent, restart at a reduced dose, and refer to the specific agent's label for those exact dose levels. For some of those rare toxicities, myelodysplastic syndrome and AML, they are recognized, labeled risk of AARP inhibitors, although rare. The reported rates are not directly comparable across agents, to be precise. The olaporib label lists an incidence of approximately 1.2%, but this figure is pooled across all olaporib indications, monotherapy and combination regimens together and is not specific to the prostate combination setting. The talazoparib figure of 0.4% derives from taproid 2, and talazoparib plus enzalutamide is not yet FDA approved in the castration sensitive setting, so the 0.4% figure should not be applied to that population. The cleanest trial specific estimate is available from Akiga's prostate trials at approximately 0.5% to 0.6%. There are three relevant points on this topic to patient counseling. The first is that latency is long, approximately 2 years for Olarep, making the first year of treatment the key surveillance window. Second, risk is associated with cumulative drug exposure. With prior platinum-based chemotherapy or radiation, increasing risk. Third, the signal warranting further workup is cytopenia that's disproportionate to the clinical picture or slow to recover after holding therapy. This should prompt a peripheral smear, bone marrow biopsy, and hematology referral. The remaining warnings on this slide are agent specific.